{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T19:23:07Z","timestamp":1785871387673,"version":"3.56.0"},"reference-count":48,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with acute- or lymphoma-type adult T-cell leukemia (ATL) have a poor outcome because of the intrinsic drug resistance to chemotherapy. Protection from apoptosis is a common feature involved in multidrug-resistance of ATL. IAP (inhibitor of apoptosis) family proteins inhibit apoptosis induced by a variety of stimuli. In this study, we investigated the expression of IAP family members (survivin, cIAP1, cIAP2, and XIAP) in the primary leukemic cells from patients with ATL. We found that survivin was overexpressed in ATL, especially in acute-type ATL. Sodium arsenite was shown to down-regulate the expression of survivin at both the protein and RNA levels in a time- and dose-dependent manner, thus inhibiting cell growth, inducing apoptosis, and enhancing the caspase-3 activity in ATL cells. Nuclear factor-\u03baB (NF-\u03baB) enhances the transcriptional activity of survivin. Sodium arsenite suppressed the constitutive NF-\u03baB activation by preventing the I\u03baB-\u03b1 degradation and the nuclear translocation of NF-\u03baB. These findings suggest that survivin is an important antiapoptotic molecule that confers drug resistance on ATL cells. Sodium arsenite was shown to down-regulate the expression of survivin through the NF-\u03baB pathway, thus inhibiting cell growth and promoting apoptosis of ATL cells.<\/jats:p>","DOI":"10.1182\/blood-2005-08-3423","type":"journal-article","created":{"date-parts":[[2006,2,24]],"date-time":"2006-02-24T01:59:19Z","timestamp":1140746359000},"page":"4880-4887","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":35,"title":["Overexpression of survivin in primary ATL cells and sodium arsenite induces apoptosis by down-regulating survivin expression in ATL cell lines"],"prefix":"10.1182","volume":"107","author":[{"given":"Xiao-Fang","family":"Che","sequence":"first","affiliation":[{"name":"From the Department of Molecular Oncology, Graduate School of Medical & Dental Sciences, and Department of Hematology and Immunology, Kagoshima University Hospital, Center for Chronic Viral Diseases, Division of Host Response, Kagoshima University, Sakuragaoka, Japan; and Pharmaceutical Research Laboratories, Toray Industries, Kamakura-city, Kanagawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Lei","family":"Zheng","sequence":"additional","affiliation":[{"name":"From the Department of Molecular Oncology, Graduate School of Medical & Dental Sciences, and Department of Hematology and Immunology, Kagoshima University Hospital, Center for Chronic Viral Diseases, Division of Host Response, Kagoshima University, Sakuragaoka, Japan; and Pharmaceutical Research Laboratories, Toray Industries, Kamakura-city, Kanagawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satsuki","family":"Owatari","sequence":"additional","affiliation":[{"name":"From the Department of Molecular Oncology, Graduate School of Medical & Dental Sciences, and Department of Hematology and Immunology, Kagoshima University Hospital, Center for Chronic Viral Diseases, Division of Host Response, Kagoshima University, Sakuragaoka, Japan; and Pharmaceutical Research Laboratories, Toray Industries, Kamakura-city, Kanagawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Mutoh","sequence":"additional","affiliation":[{"name":"From the Department of Molecular Oncology, Graduate School of Medical & Dental Sciences, and Department of Hematology and Immunology, Kagoshima University Hospital, Center for Chronic Viral Diseases, Division of Host Response, Kagoshima University, Sakuragaoka, Japan; and Pharmaceutical Research Laboratories, Toray Industries, Kamakura-city, Kanagawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takenari","family":"Gotanda","sequence":"additional","affiliation":[{"name":"From the Department of Molecular Oncology, Graduate School of Medical & Dental Sciences, and Department of Hematology and Immunology, Kagoshima University Hospital, Center for Chronic Viral Diseases, Division of Host Response, Kagoshima University, Sakuragaoka, Japan; and Pharmaceutical Research Laboratories, Toray Industries, Kamakura-city, Kanagawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hei-Cheul","family":"Jeung","sequence":"additional","affiliation":[{"name":"From the Department of Molecular Oncology, Graduate School of Medical & Dental Sciences, and Department of Hematology and Immunology, Kagoshima University Hospital, Center for Chronic Viral Diseases, Division of Host Response, Kagoshima University, Sakuragaoka, Japan; and Pharmaceutical Research Laboratories, Toray Industries, Kamakura-city, Kanagawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuhiko","family":"Furukawa","sequence":"additional","affiliation":[{"name":"From the Department of Molecular Oncology, Graduate School of Medical & Dental Sciences, and Department of Hematology and Immunology, Kagoshima University Hospital, Center for Chronic Viral Diseases, Division of Host Response, Kagoshima University, Sakuragaoka, Japan; and Pharmaceutical Research Laboratories, Toray Industries, Kamakura-city, Kanagawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Ikeda","sequence":"additional","affiliation":[{"name":"From the Department of Molecular Oncology, Graduate School of Medical & Dental Sciences, and Department of Hematology and Immunology, Kagoshima University Hospital, Center for Chronic Viral Diseases, Division of Host Response, Kagoshima University, Sakuragaoka, Japan; and Pharmaceutical Research Laboratories, Toray Industries, Kamakura-city, Kanagawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatatsu","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"From the Department of Molecular Oncology, Graduate School of Medical & Dental Sciences, and Department of Hematology and Immunology, Kagoshima University Hospital, Center for Chronic Viral Diseases, Division of Host Response, Kagoshima University, Sakuragaoka, Japan; and Pharmaceutical Research Laboratories, Toray Industries, Kamakura-city, Kanagawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misako","family":"Haraguchi","sequence":"additional","affiliation":[{"name":"From the Department of Molecular Oncology, Graduate School of Medical & Dental Sciences, and Department of Hematology and Immunology, Kagoshima University Hospital, Center for Chronic Viral Diseases, Division of Host Response, Kagoshima University, Sakuragaoka, Japan; and Pharmaceutical Research Laboratories, Toray Industries, Kamakura-city, Kanagawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomichi","family":"Arima","sequence":"additional","affiliation":[{"name":"From the Department of Molecular Oncology, Graduate School of Medical & Dental Sciences, and Department of Hematology and Immunology, Kagoshima University Hospital, Center for Chronic Viral Diseases, Division of Host Response, Kagoshima University, Sakuragaoka, Japan; and Pharmaceutical Research Laboratories, Toray Industries, Kamakura-city, Kanagawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichi","family":"Akiyama","sequence":"additional","affiliation":[{"name":"From the Department of Molecular Oncology, Graduate School of Medical & Dental Sciences, and Department of Hematology and Immunology, Kagoshima University Hospital, Center for Chronic Viral Diseases, Division of Host Response, Kagoshima University, Sakuragaoka, Japan; and Pharmaceutical Research Laboratories, Toray Industries, Kamakura-city, Kanagawa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111805243170600_REF1","doi-asserted-by":"crossref","unstructured":"Hinuma Y, Nagata K, Hanaoka M, et al. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci U S A. 1981;78: 6476-6480.","DOI":"10.1073\/pnas.78.10.6476"},{"key":"2019111805243170600_REF2","doi-asserted-by":"crossref","unstructured":"Mauxion F, Jamieson C, Yoshida M, Arai K, Sen R. Comparison of constitutive and inducible transcriptional enhancement mediated by kappa B-related sequences: modulation of activity in B cells by human T-cell leukemia virus type I tax gene. Proc Natl Acad Sci U S A. 1991;88: 2141-2145.","DOI":"10.1073\/pnas.88.6.2141"},{"key":"2019111805243170600_REF3","doi-asserted-by":"crossref","unstructured":"Mulloy JC, Kislyakova T, Cereseto A, et al. Human T-cell lymphotropic\/leukemia virus type 1 Tax abrogates p53-induced cell cycle arrest and apoptosis through its CREB\/ATF functional domain. J Virol. 1998;72: 8852-8860.","DOI":"10.1128\/JVI.72.11.8852-8860.1998"},{"key":"2019111805243170600_REF4","doi-asserted-by":"crossref","unstructured":"Fujii M, Tsuchiya H, Chuhjo T, Minamino T, Miyamoto K, Seiki M. Serum response factor has functional roles both in indirect binding to the CArG box and in the transcriptional activation function of human T-cell leukemia virus type I Tax. J Virol. 1994;68: 7275-7283.","DOI":"10.1128\/JVI.68.11.7275-7283.1994"},{"key":"2019111805243170600_REF5","doi-asserted-by":"crossref","unstructured":"Tamiya S, Matsuoka M, Etoh K, et al. Two types of defective human T-lymphotropic virus type I (HTLV-I) provirus in adult T cell leukemia. Blood. 1996;88: 3065-3073.","DOI":"10.1182\/blood.V88.8.3065.bloodjournal8883065"},{"key":"2019111805243170600_REF6","unstructured":"Knudson AG Jr. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res. 1985;45: 1437-1443."},{"key":"2019111805243170600_REF7","doi-asserted-by":"crossref","unstructured":"Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma: a report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79: 428-437.","DOI":"10.1111\/j.1365-2141.1991.tb08051.x"},{"key":"2019111805243170600_REF8","doi-asserted-by":"crossref","unstructured":"Kuwazuru Y, Hanada S, Furukawa T, et al. Expression of P-glycoprotein in adult T-cell leukemia cells. Blood. 1990;76: 2065-2071.","DOI":"10.1182\/blood.V76.10.2065.2065"},{"key":"2019111805243170600_REF9","unstructured":"Ohno N, Tani A, Chen ZS, et al. Prognostic significance of multidrug resistance protein in adult T-cell leukemia. Clin Cancer Res. 2001;7: 3120-3126."},{"key":"2019111805243170600_REF10","doi-asserted-by":"crossref","unstructured":"Ohno N, Tani A, Uozumi K, et al. Expression of functional lung resistance\u2014related protein predicts poor outcome in adult T-cell leukemia. Blood. 2001;98: 1160-1165.","DOI":"10.1182\/blood.V98.4.1160"},{"key":"2019111805243170600_REF11","doi-asserted-by":"crossref","unstructured":"Mori N, Yamada Y, Ikeda S, et al. Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood. 2002;100: 1828-1834.","DOI":"10.1182\/blood-2002-01-0151"},{"key":"2019111805243170600_REF12","doi-asserted-by":"crossref","unstructured":"LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibi tors of apoptosis (IAPs) and their emerging role in cancer. Oncogene. 1998;17: 3247-3259.","DOI":"10.1038\/sj.onc.1202569"},{"key":"2019111805243170600_REF13","unstructured":"Moriai R, Asanuma K, Kobayashi D, et al. Quantitative analysis of the anti-apoptotic gene survivin expression in malignant haematopoietic cells. Anticancer Res. 2001;21: 595-600."},{"key":"2019111805243170600_REF14","doi-asserted-by":"crossref","unstructured":"Nakagawa Y, Yamaguchi S, Hasegawa M, et al. Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia. Leukemia Res. 2004;28: 487-494.","DOI":"10.1016\/j.leukres.2003.10.013"},{"key":"2019111805243170600_REF15","doi-asserted-by":"crossref","unstructured":"Kamihira S, Yamada Y, Hirakata Y, et al. Aberrant expression of caspase cascade regulatory genes in adult T-cell leukaemia: survivin is an important determinant for prognosis. Br J Haematol. 2001;114: 63-69.","DOI":"10.1046\/j.1365-2141.2001.02902.x"},{"key":"2019111805243170600_REF16","doi-asserted-by":"crossref","unstructured":"Adida C, Recher C, Raffoux E, et al. Expression and prognostic significance of survivin in de novo acute myeloid leukaemia. Br J Haematol. 2000;111: 196-203.","DOI":"10.1046\/j.1365-2141.2000.02328.x"},{"key":"2019111805243170600_","unstructured":"Adida C, Haioun C, Gaulard P, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood. 2000;96: 1921-1925."},{"key":"2019111805243170600_","doi-asserted-by":"crossref","unstructured":"Kim MJ, Lim KY, Kim JW, Nam IW, Lee JH, Myoung H. Stage and mRNA expression of survivin in lymph node as prognostic indicators in patients with oral squamous cell carcinoma. Cancer Lett. 2005;224: 253-261.","DOI":"10.1016\/j.canlet.2005.01.009"},{"key":"2019111805243170600_REF19","doi-asserted-by":"crossref","unstructured":"Ku JH, Kwak C, Lee HS, Park HK, Lee E, Lee SE. Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. J Urol. 2004;171: 631-635.","DOI":"10.1097\/01.ju.0000106082.44786.3b"},{"key":"2019111805243170600_REF20","doi-asserted-by":"crossref","unstructured":"Ishitsuka K, Hanada S, Suzuki S, et al. Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids. Br J Haematol. 1998;103: 721-728.","DOI":"10.1046\/j.1365-2141.1998.01068.x"},{"key":"2019111805243170600_REF21","doi-asserted-by":"crossref","unstructured":"Ishitsuka K, Hanada S, Uozumi K, Utsunomiya A, Arima T. Arsenic trioxide and the growth of human T-cell leukemia virus type I infected T-cell lines. Leuk Lymphoma. 2000;37: 649-655.","DOI":"10.3109\/10428190009058521"},{"key":"2019111805243170600_REF22","doi-asserted-by":"crossref","unstructured":"Ikeda R, Furukawa T, Kitazono M, et al. Molecular basis for the inhibition of hypoxia-induced apoptosis by 2-deoxy-D-ribose. Biochem Biophys Res Commun. 2002;291: 806-812.","DOI":"10.1006\/bbrc.2002.6432"},{"key":"2019111805243170600_REF23","unstructured":"Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol. 1998;152: 43-49."},{"key":"2019111805243170600_REF24","doi-asserted-by":"crossref","unstructured":"Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3: 917-921.","DOI":"10.1038\/nm0897-917"},{"key":"2019111805243170600_REF25","doi-asserted-by":"crossref","unstructured":"Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3: 46-54.","DOI":"10.1038\/nrc968"},{"key":"2019111805243170600_REF26","unstructured":"Olie RA, Simoes-Wust AP, Baumann B, et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 2000;60: 2805-2809."},{"key":"2019111805243170600_REF27","doi-asserted-by":"crossref","unstructured":"Zhang M, Mukherjee N, Bermudez RS, et al. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate. 2005;64: 293-302.","DOI":"10.1002\/pros.20263"},{"key":"2019111805243170600_REF28","doi-asserted-by":"crossref","unstructured":"Pennati M, Binda M, De Cesare M, et al. Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis. 2004;25: 1129-1136.","DOI":"10.1093\/carcin\/bgh107"},{"key":"2019111805243170600_REF29","unstructured":"Wang L, Zhang GM, Feng ZH. Down-regulation of survivin expression reversed multidrug resistance in adriamycin-resistant HL-60\/ADR cell line. Acta Pharmacol Sin. 2003;24: 1235-1240."},{"key":"2019111805243170600_REF30","doi-asserted-by":"crossref","unstructured":"Tu SP, Cui JT, Liston P, et al. Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant. Gastroenterology. 2005;128: 361-375.","DOI":"10.1053\/j.gastro.2004.11.058"},{"key":"2019111805243170600_REF31","doi-asserted-by":"crossref","unstructured":"Lanotte M, Martin-Thouvenin V, Najman S, Balerini P, Valensi F, Berger R. NB4, a maturation inducible cell line with t(15;17) marker isolated from a human acute promyelocytic leukemia (M3). Blood. 1991;77: 1080-1086.","DOI":"10.1182\/blood.V77.5.1080.1080"},{"key":"2019111805243170600_REF32","doi-asserted-by":"crossref","unstructured":"Chow SK, Chan JY, Fung KP. Inhibition of cell proliferation and the action mechanisms of arsenic trioxide (As2O3) on human breast cancer cells. J Cell Biochem. 2004;93: 173-187.","DOI":"10.1002\/jcb.20102"},{"key":"2019111805243170600_","doi-asserted-by":"crossref","unstructured":"Shen ZY, Shen J, Li QS, Chen CY, Chen JY, Yi Z. Morphological and functional changes of mitochondria in apoptotic esophageal carcinoma cells induced by arsenic trioxide. World J Gastroenterol. 2002;8: 31-35.","DOI":"10.3748\/wjg.v8.i1.31"},{"key":"2019111805243170600_","doi-asserted-by":"crossref","unstructured":"Bruno B, Rotta M, Giaccone L, et al. New drugs for treatment of multiple myeloma. Lancet Oncol. 2004;5: 430-442.","DOI":"10.1016\/S1470-2045(04)01511-6"},{"key":"2019111805243170600_REF35","doi-asserted-by":"crossref","unstructured":"Ishitsuka K, Ikeda R, Utsunomiya A, et al. Arsenic trioxide induces apoptosis in HTLV-I infected T-cell lines and fresh adult T-cell leukemia cells through CD95 or tumor necrosis factor alpha receptor independent caspase activation. Leuk Lymphoma. 2002;43: 1107-1114.","DOI":"10.1080\/10428190290021461"},{"key":"2019111805243170600_REF36","doi-asserted-by":"crossref","unstructured":"Bazarbachi A, El-Sabban ME, Nasr R, et al. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I-transformed cells. Blood. 1999;93: 278-283.","DOI":"10.1182\/blood.V93.1.278"},{"key":"2019111805243170600_REF37","doi-asserted-by":"crossref","unstructured":"Shi Y. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell. 2002;9: 459-470.","DOI":"10.1016\/S1097-2765(02)00482-3"},{"key":"2019111805243170600_REF38","doi-asserted-by":"crossref","unstructured":"Shin S, Sung BJ, Cho YS, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry. 2001;40: 1117-1123.","DOI":"10.1021\/bi001603q"},{"key":"2019111805243170600_REF39","doi-asserted-by":"crossref","unstructured":"Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 2000;102: 33-42.","DOI":"10.1016\/S0092-8674(00)00008-8"},{"key":"2019111805243170600_REF40","doi-asserted-by":"crossref","unstructured":"Tu SP, Cui JT, Liston P, et al. Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant. Gastroenterology. 2005;128: 361-375.","DOI":"10.1053\/j.gastro.2004.11.058"},{"key":"2019111805243170600_REF41","unstructured":"El-Sabban ME, Nasr R, Dbaibo G, et al. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood. 2000;96: 2849-2855."},{"key":"2019111805243170600_REF42","doi-asserted-by":"crossref","unstructured":"Han SS, Kim K, Hahm ER, et al. L-ascorbic acid represses constitutive activation of NF-kappaB and COX-2 expression in human acute myeloid leukemia, HL-60. J Cell Biochem. 2004;93: 257-270.","DOI":"10.1002\/jcb.20116"},{"key":"2019111805243170600_REF43","doi-asserted-by":"crossref","unstructured":"Kawakami H, Tomita M, Matsuda T, et al. Transcriptional activation of survivin through the NF-kappaB pathway by human T-cell leukemia virus type I tax. Int J Cancer. 2005;115: 967-974.","DOI":"10.1002\/ijc.20954"},{"key":"2019111805243170600_REF44","doi-asserted-by":"crossref","unstructured":"Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer. 2005;5: 297-309.","DOI":"10.1038\/nrc1588"},{"key":"2019111805243170600_REF45","doi-asserted-by":"crossref","unstructured":"Shishodia S, Aggarwal BB. Guggulsterone inhibits NF-kappaB and IkappaBalpha kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis. J Biol Chem. 2004;279: 47148-47158.","DOI":"10.1074\/jbc.M408093200"},{"key":"2019111805243170600_REF46","doi-asserted-by":"crossref","unstructured":"Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), II: clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89: 3354-3360.","DOI":"10.1182\/blood.V89.9.3354"},{"key":"2019111805243170600_REF47","doi-asserted-by":"crossref","unstructured":"Hermine O, Dombret H, Poupon J, et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed\/refractory adult T-cell leukemia\/lymphoma. Hematol J. 2004;5: 130-134.","DOI":"10.1038\/sj.thj.6200374"},{"key":"2019111805243170600_REF48","doi-asserted-by":"crossref","unstructured":"Leslie EM, Haimeur A, Waalkes MP. Arsenic transport by the human multidrug resistance protein 1 (MRP1\/ABCC1): evidence that a tri-glutathione conjugate is required. J Biol Chem. 2004;279: 32700-32708.","DOI":"10.1074\/jbc.M404912200"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/12\/4880\/1279037\/zh801206004880.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/12\/4880\/1279037\/zh801206004880.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,12]],"date-time":"2020-04-12T22:03:12Z","timestamp":1586728992000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/12\/4880\/129281\/Overexpression-of-survivin-in-primary-ATL-cells"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,15]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2006,6,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-08-3423","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,6,15]]}}}